Wedbush upgraded Replimune (REPL) to Outperform from Neutral with a price target of $18, up from $4.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune announces FDA acceptance of BLA resubmission of RP1
- Replimune announces new ad hoc analysis from IGNYTE phase 2 cohort of RP1
- Intel downgraded, Tesla upgraded: Wall Street’s top analyst calls
- Replimune downgraded to Underweight from Neutral at JPMorgan
- Replimune Group Completes FDA Meeting on RP1 Application